Mitotic and in situ end-labeling apoptotic indices as prognostic markers in malignant mesothelioma
Related Experiment Video
Updated: Oct 15, 2026
Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022
T W Beer1, N J Carr, M A Whittaker
1Department of Histopathology, The Royal Hospital Haslar, Hampshire, UK.
Abstract:
The prognostic role of mitotic and apoptotic indices in 60 patients with malignant mesothelioma was examined on hematoxylin-eosin-stained sections. The findings were compared with apoptotic indices determined by in situ end labeling (ISEL) in 35 of the cases. There was a significant survival advantage associated with lower mitotic counts and a lower apoptotic index defined by ISEL (P < .05). There was no association between the apoptotic index derived from the hematoxylin-eosin-stained sections and prognosis (P = .90). However, there was a positive association between the apoptotic counts calculated from hematoxylin-eosin- and ISEL-stained sections (P < .01). The mitotic count and ISEL apoptotic index are potentially useful markers of prognosis in malignant mesothelioma.
